Dr. Jingyi Wu has received a 2026 BIDMC Translational Research Hub Spark Grant for her project, “Epigenetic Mechanisms of the IDH Inhibitor in Glioma.”
Dr. Jingyi Wu, Assistant Professor of Medicine at Beth Israel Deaconess Medical Center and Harvard Medical School, has been awarded the prestigious National Cancer Institute (NCI) Transition Career...
A new collaborative study led by scientists from the Broad Institute of MIT and Harvard, Dana-Farber Cancer Institute (DFCI), and Beth Israel Deaconess Medical Center (BIDMC) has uncovered how two...
A collaborative team led by Dr. Jingyi Wu at the Dana-Farber Cancer Institute and Massachusetts General Hospital has revealed how epigenetic and genetic forces drive the deadly progression of IDH...
